A leading oncologist proposes classifying metastatic cancer by molecular alterations rather than organ origin, arguing that the shift could accelerate drug access.

Over a five-year span, women who used complementary and alternative medicine had a greater mortality rate than those who ...

The Bar brand founder, 42, was diagnosed with breast cancer while attempting her sixth IVF egg retrieval in 2024 ...

The alternative medicine industry is expanding rapidly, fueled in large part by the surge of health-related content on social ...

As a world leader in the immuno-oncology field, Dr. Zihai Li has long been at the forefront of cancer immunotherapy.

A one‑year course of T‑DM1 offers excellent cancer‑free survival for early HER2‑positive breast cancer, with far less nerve ...

Real-world community study finds Enhertu in HER2-low metastatic breast cancer has trial-like discontinuation rates; ILD remains key toxicity.

Through a donor-funded Hospital at Home program at Alberta Children’s Hospital, specialized oncology nurses delivered some ...

Are time commitments related to cancer care toxic? Depends on who you ask.The term “time toxicity” has become cancer jargon over the past few years, sparking research into how much time patients spend ...

Researchers launch a public immune atlas of pancreatic cancer therapy responses, allowing the public to rapidly link pancreatic cancer immunotherapy trials to immune shifts and outcomes. Imagine ...

As previously presented, gedatolisib + palbociclib + fulvestrant ('gedatolisib triplet”) and gedatolisib + fulvestrant ('gedatolisib doublet”) reduced the risk of disease progression or death versus ...

A Roche Holding AG study of its experimental breast-cancer drug in combination with another treatment failed to meet the ...